Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Astellas to Acquire US Biotech Ocata Therapeutics for US$379 Million
November 11, 2015
- Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
- Chugai, Kowa Expand Licensing Deal for Deberza
November 11, 2015
- Ethical Dug Sales Climb 7.8% in September: Crecon Report
November 11, 2015
- Fujifilm’s AML Drug Candidate to Enter PI in US
November 11, 2015
- Shionogi, GSK to Independently Develop Jointly Researched Antibiotics
November 10, 2015
- Jardiance Jumps into Top 20 Ranking on Physicians’ Recollection: Anterio
November 10, 2015
- AZ’s Lung Cancer Treatment Gets Priority Review Status in Japan
November 9, 2015
- Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
November 6, 2015
- Ono Now Has Oncology Sales Force of 180, Eyes Lung Cancer Indication for Opdivo
November 6, 2015
- Nichi-Iko Eyes Generic Production Capacity of 21 Billion Tablets by 2021
November 5, 2015
- AbbVie Files Humira for Non-Infectious Uveitis
November 5, 2015
- Astellas to Transfer Kiyosu Plant Business to MicroBiopharm Japan
November 4, 2015
- Mochida Seeks Japan Approval of Ulcerative Colitis Drug
November 4, 2015
- AbbVie Files Parkinson’s Treatment in Japan
November 4, 2015
- Edoxaban Flounders in US but No Change to FY2017 Biz Targets: Daiichi Sankyo CEO
November 4, 2015
- Mitsubishi Tanabe to Cut Back on Jobs in Japan
November 4, 2015
- Mitsubishi Tanabe Sales Tick Up as Royalty Income Increases
November 4, 2015
- Daiichi Sankyo Recalls Measles, Rubella Vaccines
November 4, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…